Cerenome, Inc.（CNSY）資訊與事件CNSYCerenome, Inc.

Cerenome Presents Preclinical Data on REYOBIQ Showing Antitumor Activity

Cerenome announced that new preclinical data presented at the 16th Biennial Rivkin Ovarian Cancer Research Symposium illustrate the emerging immunomodulatory properties of REYOBIQ, its lead investigational targeted radiotherapeutic. In two mouse models of aggressive epithelial ovarian cancer, treatment with rhenium obisbemeda, the active agent in REYOBIQ, was associated with tumor injury and changes in the tumor microenvironment. Combination treatment with anti-PD-1 checkpoint blockade also showed improved antitumor activity, extending median survival to 65 days, longer than control or either agent alone. "Turning 'cold' or immunologically resistant tumors into 'hot' or immunologically responsive tumors is the major limitation for the broader use of checkpoint inhibitors," said Eric Daniels, chief development officer.